Well crafted, positive results for AstraZeneca ’s Brilinta and an unexpected coup for Boehringer Ingelheim ’s Pradaxa dominated the headlines following this year’s European Society of Cardiology’s Annual Meeting in Barcelona. Both announcements have a number of important implications for the wider cardiology market, from both therapeutic and commercial perspectives
View post:
buying antibiotics online title=”Datamonitor: AstraZeneca and Boehringer Ingelheim steal limelight at European Society of Cardiology meeting”>Datamonitor: AstraZeneca and Boehringer Ingelheim steal limelight at European Society of Cardiology meeting
drugs online